Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men
- 1 March 2004
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (3) , 804-808
- https://doi.org/10.1128/aac.48.3.804-808.2004
Abstract
Posaconazole is a potent broad-spectrum azole antifungal agent in clinical development for the treatment of invasive fungal infections. This study evaluated the potential for a pH-dependent pharmacokinetic interaction between posaconazole and an antacid (Mylanta), under fasting and nonfasting conditions. Twelve men completed this randomized, four-period crossover, single-dose study. Subjects received 200 mg of posaconazole following a 10-h fast, with 20 ml of Mylanta and a 10-h fast, with 20 ml of Mylanta and a high-fat breakfast, and with a high-fat breakfast alone. Antacid coadministration had no statistically significant effects on posaconazole bioavailability under fasting or nonfasting conditions. In the fasting state, antacid slightly increased the relative oral bioavailability of posaconazole by 15% (P = 0.296); in the nonfasting state, antacid decreased the relative bioavailability of posaconazole by 12% (P = 0.352). Food increased the relative oral bioavailability of posaconazole by 400% (P = 0.001). In conclusion, the effect of antacid on posaconazole exposure in the fasting or nonfasting state was small and is not considered clinically significant.Keywords
This publication has 33 references indexed in Scilit:
- Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy AdultsAntimicrobial Agents and Chemotherapy, 2003
- Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipientsSeminars in Respiratory Infections, 2002
- In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of ZygomycetesAntimicrobial Agents and Chemotherapy, 2002
- In Vitro and In Vivo Activities of Posaconazole against Coccidioides immitisAntimicrobial Agents and Chemotherapy, 2002
- Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000Antimicrobial Agents and Chemotherapy, 2002
- Antifungal use in HIV infectionExpert Opinion on Pharmacotherapy, 2002
- In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Activities of Four Novel Triazoles against Scedosporium sppAntimicrobial Agents and Chemotherapy, 2001
- Infections Due to Resistant Candida Species in Patients with Cancer Who Are Receiving ChemotherapyClinical Infectious Diseases, 1994
- Fungal Infections in Solid-Organ TransplantationClinical Infectious Diseases, 1993